Top

Published in:

01-02-2017 | Letter to the Editor

Author’s Reply to Srinivas: “Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer”

Authors: Steven Xu, Peter De Porre

Published in: Clinical Pharmacokinetics | Issue 2/2017

Excerpt

We thank Dr. Srinivas for his interest in the publication and his constructive comments [1]. We welcome the opportunity to clarify and discuss additional key points of our abiraterone pharmacokinetics-prostate-specific antigen (PSA) modeling analysis. …

Srinivas NR. Comment on: “Modeling the relationship between exposure to abiraterone and prostate-specific antigen dynamics in patients with metastatic castration-resistant prostate cancer”. Clin Pharmacokinet. 2016;. doi:10.1007/s40262-016-0468-2.PubMed

Xu XS, Ryan CJ, Stuyckens K, et al. Modeling the relationship between exposure to abiraterone and prostate-specific antigen dynamics in patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet. 2016. [Epub ahead of print].

Stuyckens K, Saad F, Xu XS, et al. Population pharmacokinetic analysis of abiraterone in chemotherapy-naive and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet. 2014;53:1149–60.CrossRefPubMed

Attard G, Reid AHM, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563–71.CrossRefPubMed

Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010;28:1481–8.CrossRefPubMedPubMedCentral

Reid AHM, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010;28:1489–95.CrossRefPubMedPubMedCentral

Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010;28:1496–501.CrossRefPubMedPubMedCentral

Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983–92.CrossRefPubMed

Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–60.CrossRefPubMed

10.

Carles J, Davis ID, de Bono JS, et al. Safety of long-term treatment of chemotherapy-naïve metastatic castration-resistant prostate cancer patients with abiraterone acetate plus prednisone for ≥4 years. Poster presented at the European Society of Medical Oncology 2016 Congress, 7–11 October 2016, Copenhagen, Denmark. Abstr No 740P

11.

Emamekhoo H, Li Z, Sharifi N. Clinical significance of D4A in prostate cancer therapy with abiraterone. Cell Cycle. 2015;14:3213–4.CrossRefPubMedPubMedCentral

12.

Li Z, Bishop A, Alyamani M, et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature. 2015;523:347–51.CrossRefPubMedPubMedCentral

Title: Author’s Reply to Srinivas: “Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer”
Authors: Steven Xu
Peter De Porre
Publication date: 01-02-2017
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 2/2017
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-016-0469-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Author’s Reply to Srinivas: “Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer”

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2017

Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus

Discrepancies between the Cockcroft–Gault and Chronic Kidney Disease Epidemiology (CKD-EPI) Equations: Implications for Refining Drug Dosage Adjustment Strategies

Authors’ Reply to Kamel et al.: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study”

Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study

Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies

Comment on: “Modeling the Relationship between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer”